Previous close | 29.45 |
Open | 29.05 |
Bid | 27.02 x 1000 |
Ask | 27.14 x 900 |
Day's range | 27.04 - 29.00 |
52-week range | 18.05 - 34.63 |
Volume | |
Avg. volume | 795,605 |
Market cap | 3.603B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 3.25 |
EPS (TTM) | 8.32 |
Earnings date | 22 Feb 2023 - 27 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 54.43 |
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors – SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors h
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Doing so requires a substantial compound annual growth rate (CAGR) exceeding 58%. You're not likely to see such a rate among value stocks, which for all their consistency rarely grow at that pace. Two companies where I see that kind of progress over the next five years are Vir Biotechnology (NASDAQ: VIR) and Albemarle (NYSE: ALB).